A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
Author(s): Farlow M, Anand R, Messina J Jr, Hartman R, Veach J
Affiliation(s): Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202-5111, USA. mfarlow@iupui.edu
Publication date & source: 2000, Eur Neurol., 44(4):236-41.
Publication type: Clinical Trial; Randomized Controlled Trial
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright 2000 S. Karger AG, Basel
|